Monoclonal Antibodies in Cancer Therapy: Mechanisms, Successes and Limitations
Monoclonal Antibodies in Cancer Therapy: Mechanisms, Successes and Limitations
复制标题
DOI：
10.7727/wimj.2013.241
复制
发表时间：
2014-10-01
影响因子：
0.1
通讯作者：
Gossell-Williams, M.
中科院分区：
文献类型：
--
作者：
Coulson, A.;Levy, A.;Gossell-Williams, M.
利妥昔单抗是1997年批准用于癌症治疗的第一个化疗单克隆抗体（CmAb），并且显著改善了非霍奇金淋巴瘤的临床结果。从那时起，许多CmAb已被开发和批准用于治疗各种血液和实体人类癌症。在这篇综述中，分类，疗效和显着降低毒性的CmAbs可用于在美国。最后，CmAbs的局限性和未来的考虑进行了探讨。
Rituximab was the first chemotherapeutic monoclonal antibody (CmAb) approved for clinical use in cancer therapeutics in 1997 and has significantly improved the clinical outcomes in non-Hodgkin's lymphoma. Since then, numerous CmAbs have been developed and approved for the treatment of various haematologic and solid human cancers. In this review, the classification, efficacy and significantly reduced toxicity of CmAbs available for use in the United States of America are presented. Finally, the limitations of CmAbs and future considerations are explored.